Targeting dendritic cells with TLR-2 ligand-coated nanoparticles loaded with Mycobacterium tuberculosis epitope induce antituberculosis immunity

Novel vaccination strategies are crucial to efficiently control tuberculosis, as proposed by the World Health Organization un-der its flagship program End TB Strategy. However, the emer-gence of drug-resistant strains of Mycobacterium tuberculosis (Mtb), particularly in those coinfected with HIV-AIDS, consti-tutes a major impediment to achieving this goal. We report here a novel vaccination strategy that involves synthesizing a formula-tion of an immunodominant peptide derived from the Acr1 pro-tein of Mtb. This nanoformulation in addition displayed on the surface a toll-like receptor-2 ligand to offer to target dendritic cells (DCs). Our results showed an efficient uptake of such a concoction by DCs in a predominantly toll-like receptor-2-dependent pathway. These DCs produced elevated levels of nitric oxide, proinflammatory cytokines interleukin-6, interleukin-12, and tumor necrosis factor-alpha, and upregulated the surface expression of major histocompatibility complex class II molecules as well as costimulatory molecules such as CD80 and CD86. Animals injected with such a vaccine mounted a significantly higher response of effector and memory Th1 cells and Th17 cells. Furthermore, we noticed a reduction in the bacterial load in the lungs of animals challenged with aerosolized live Mtb. Therefore, our findings indicated that the described vaccine triggered pro-tective anti-Mtb immunity to control the tuberculosis infection.

Automated summary

Novel vaccination strategies are crucial for controlling tuberculosis, but drug-resistant strains of Mycobacterium tuberculosis are a major obstacle. A new vaccine formulation was developed, which effectively triggered an immune response to control tuberculosis infection.